Two blood factors help with the individualized prognosis treatment of Alzheimer's disease

There are about 50 million people with dementia worldwide, and the prevalence rate is expected to double by 2030.
50 to 70 per cent of dementia cases are caused by Alzheimer's disease (AD).
mild cognitive impairment (MCI) before the stage of dementia.
accurate prognostion is important in MCI because it can lead to cognitive decline and dementia (due to AD or other diseases), or benign and stable consequences.
if AD's disease improvement treatment becomes available, an accurate prognostication may be important to guide the treatment of MCI patients.
recently, researchers published a paper in the journal Nature Aging, reporting that they have developed models that use β-amyloid proteins (A beta), tau, and neurodegenerative plasma biomarkers to predict the cognitive decline of mild cognitive impairment (MCI).
the study included 573 MCI patients from the BioFINDER Study in Sweden and the Alzheimer's Neuroimaging Initiative (ADNI).
results of this study are longitudinal cognition and conversion to Alzheimer's disease (AD) dementia.
combined with tau's phosphorylation (P-tau181) and neural silk light (NfL) in Suline 181, but excluding models of A-beta 42/A beta-40, the best performance was predicted in all models (bioFINDER's four-year conversion to AD's sub-curve area of 0.88, validated in ADNI), was stronger than the basic model of age, gender, education, and baseline cognition, and showed similar performance to the basic model of cerebrospinal biocognitive.
, the study introduced an open online tool based on THEI individualized prognosis based on the combined plasma biomarker model.
combination of plasma biomarkers may be of high value in identifying MCI individuals who may progress to AD dementia in clinical trials and practices.
。